MCID: ASP030
MIFTS: 40

Aspirin Resistance

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Aspirin Resistance

MalaCards integrated aliases for Aspirin Resistance:

Name: Aspirin Resistance 57
Aspirin, Resistance to Cardioprotective Effect of 57
Aspirin, Resistance to Antithrombotic Effect of 57
Aspirin Cardioprotective Effect of 57
Aspirin Antithrombotic Effect of 57

Classifications:



External Ids:

OMIM® 57 608223

Summaries for Aspirin Resistance

OMIM® : 57 Aspirin (acetylsalicylic acid) is a classic nonsteroidal antiinflammatory agent that irreversibly inhibits type I cyclooxygenase (PTGS1, or COX1; 176805) in platelets, resulting in decreased production of thromboxane A2 (TXA2) and inhibition of platelet aggregation. Because of this feature, it is used therapeutically to prevent cardiothrombotic events. Individuals show a variable response to the drug, referred to as aspirin ineffectiveness or resistance, in which not all individuals or populations appear to receive the full prophylactic or therapeutic benefits (summary by Zhou et al., 2011). Halushka and Halushka (2002) discussed a possible basis for resistance to the cardioprotective effect of aspirin. (608223) (Updated 05-Apr-2021)

MalaCards based summary : Aspirin Resistance, also known as aspirin, resistance to cardioprotective effect of, is related to clopidogrel resistance and thrombosis. An important gene associated with Aspirin Resistance is PTGS1 (Prostaglandin-Endoperoxide Synthase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Development VEGF signaling via VEGFR2 - generic cascades. The drugs Clopidogrel and Heparin have been mentioned in the context of this disorder. Affiliated tissues include heart, whole blood and endothelial, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Aspirin Resistance

Diseases related to Aspirin Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 clopidogrel resistance 30.1 PTGS2 ITGB3
2 thrombosis 29.8 ITGB3 F5 F2
3 peripheral vascular disease 29.8 F5 F2 APOB
4 stroke, ischemic 29.6 F5 F2 APOB
5 homocysteinemia 29.6 F5 F2
6 mediastinitis 29.6 F5 F2
7 post-thrombotic syndrome 29.5 F5 F2
8 cerebrovascular disease 29.5 ITGB3 F5 F2 APOB
9 essential thrombocythemia 29.5 PTGS1 ITGB3 F2
10 thrombophilia due to thrombin defect 29.4 F5 F2
11 varicose veins 29.4 F5 F2
12 active peptic ulcer disease 29.2 PTGS2 PTGS1 F2
13 thrombophilia 29.2 ITGB3 F5 F2
14 polycythemia vera 29.2 ITGB3 F5 F2
15 type 2 diabetes mellitus 29.0 PTGS2 ITGB3 F2 APOB
16 vascular disease 28.9 PTGS2 PTGS1 ITGB3 F5 F2 APOB
17 heart disease 28.6 PTGS2 PTGS1 ITGB3 F5 F2 APOB
18 myocardial infarction 28.5 PTGS2 PTGS1 ITGB3 F5 F2 APOB
19 arteries, anomalies of 10.5
20 lipoprotein quantitative trait locus 10.5
21 ischemia 10.5
22 intermediate coronary syndrome 10.3
23 hypercholesterolemia, familial, 1 10.2
24 coronary heart disease 1 10.2
25 gas gangrene 10.2
26 transient cerebral ischemia 10.1
27 lipid metabolism disorder 10.1
28 diabetes mellitus 10.1
29 peptic ulcer disease 10.1 PTGS2 PTGS1
30 kidney papillary necrosis 10.1 PTGS2 PTGS1
31 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1 PTGS2 PTGS1
32 chronic cystitis 10.1 PTGS2 PTGS1
33 antenatal bartter syndrome 10.1 PTGS2 PTGS1
34 hydrops, lactic acidosis, and sideroblastic anemia 10.1 PTGS2 PTGS1
35 sticky platelet syndrome 10.1 ITGB3 F5
36 morphine dependence 10.1 PTGS2 PTGS1
37 pre-eclampsia 10.1
38 chronic acquired demyelinating polyneuropathy 10.1
39 coronary thrombosis 10.1 PTGS2 ITGB3
40 viral encephalitis 10.1 PTGS2 PTGS1
41 atherosclerosis susceptibility 10.0
42 body mass index quantitative trait locus 1 10.0
43 angina pectoris 10.0
44 diabetic angiopathy 10.0
45 carotid stenosis 10.0
46 intermittent claudication 10.0
47 gastric ulcer 10.0 PTGS2 PTGS1
48 proteasome-associated autoinflammatory syndrome 1 10.0 PTGS2 PTGS1
49 limb ischemia 10.0
50 eclampsia 10.0

Graphical network of the top 20 diseases related to Aspirin Resistance:



Diseases related to Aspirin Resistance

Symptoms & Phenotypes for Aspirin Resistance

Clinical features from OMIM®:

608223 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Aspirin Resistance:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.99 APOB F2 F5 ITGB3 PTGS1 PTGS2
2 growth/size/body region MP:0005378 9.93 APOB F2 F5 ITGB3 PTGS1 PTGS2
3 homeostasis/metabolism MP:0005376 9.91 APOB F2 F5 ITGB3 PTGS1 PTGS2
4 embryo MP:0005380 9.88 APOB F2 F5 ITGB3 PTGS2
5 digestive/alimentary MP:0005381 9.8 F2 ITGB3 PTGS1 PTGS2
6 integument MP:0010771 9.8 F2 F5 ITGB3 PTGS1 PTGS2
7 mortality/aging MP:0010768 9.8 APOB F2 F5 ITGB3 PTGS1 PTGS2
8 liver/biliary system MP:0005370 9.67 APOB F5 ITGB3 PTGS2
9 muscle MP:0005369 9.65 APOB F2 ITGB3 PTGS1 PTGS2
10 nervous system MP:0003631 9.63 APOB F2 F5 ITGB3 PTGS1 PTGS2
11 reproductive system MP:0005389 9.35 APOB F2 ITGB3 PTGS1 PTGS2
12 respiratory system MP:0005388 8.92 F2 ITGB3 PTGS1 PTGS2

Drugs & Therapeutics for Aspirin Resistance

Drugs for Aspirin Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
2
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
3
Tirofiban Approved Phase 4 144494-65-5 60947
4
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
5
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
6
Dipyridamole Approved Phase 4 58-32-2 3108
7
Pravastatin Approved Phase 4 81093-37-0 54687
8
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
9
Atorvastatin Approved Phase 4 134523-00-5 60823
10
Lysine Approved, Nutraceutical Phase 4 56-87-1 5962
11 Acetylsalicylic acid lysinate Phase 4
12 polysaccharide-K Phase 4
13 Antibiotics, Antitubercular Phase 4
14 Protective Agents Phase 4
15 Anti-Infective Agents Phase 4
16 Adjuvants, Immunologic Phase 4
17 Radiation-Protective Agents Phase 4
18 Antiviral Agents Phase 4
19 Immunologic Factors Phase 4
20 interferons Phase 4
21 calcium heparin Phase 4
22 Anti-Bacterial Agents Phase 4
23 Neurotransmitter Agents Phase 4
24 Purinergic P2Y Receptor Antagonists Phase 4
25 Vasodilator Agents Phase 4
26 Anti-Asthmatic Agents Phase 4
27 Neuroprotective Agents Phase 4
28 Respiratory System Agents Phase 4
29 Phosphodiesterase 3 Inhibitors Phase 4
30 Bronchodilator Agents Phase 4
31 Phosphodiesterase Inhibitors Phase 4
32 Aspirin, Dipyridamole Drug Combination Phase 4
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
34 Chinese Salvia Phase 4
35 Antimetabolites Phase 4
36 Anticholesteremic Agents Phase 4
37 Lipid Regulating Agents Phase 4
38 Calcium, Dietary Phase 4
39 Hypolipidemic Agents Phase 4
40
Calcium Nutraceutical Phase 4 7440-70-2 271
41
Abciximab Approved Phase 2 143653-53-6
42
Eptifibatide Approved, Investigational Phase 2 188627-80-7 123610
43
Ticlopidine Approved Phase 2 55142-85-3 5472
44
Cangrelor Approved Phase 2 163706-06-7 9854012
45
Nutmeg Approved Phase 2
46 Omega 3 Fatty Acid Phase 1, Phase 2
47 Cytochrome P-450 Enzyme Inhibitors Phase 2
48 Anticoagulants Phase 2
49 Mace Phase 2
50 Prasugrel hydrochloride Phase 2 389574-19-0

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
2 Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients Unknown status NCT01935193 Phase 4 lysine acetylsalicylate
3 Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Completed NCT00398463 Phase 4 Tirofiban;Placebo
4 Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. Completed NCT00222261 Phase 4 aspirin;clopidogrel
5 Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting Completed NCT01159639 Phase 4 Clopidogrel
6 Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients Completed NCT00446641 Phase 4 Cilostazol;placebo
7 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
8 Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index With Stable Angina Pectoris of Coronary Heart Disease as an Example Completed NCT01502943 Phase 4 Louxiangdan Tongxin granules;TCM granules placebo;Chixiangshen Tongxin granules;TCM granule placebo plus western basis treatment;Western basis treatment
9 Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis Withdrawn NCT01198379 Phase 4 aspirin;Placebo
10 Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI Unknown status NCT00697021 Phase 3 Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG;Aspirin 100mg and Plavix 75mg
11 The Effects of Omega-3 Fatty Acids on Aspirin Resistance Completed NCT00771914 Phase 1, Phase 2 Aspirin;Lovaza;Both Aspirin and Lovaza
12 A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary Intervention Completed NCT01103440 Phase 2 Intravenous Glycoprotein inhibitor + ASA, Clopidogrel;Antiplatelet Therapy (ASA, Clopidogrel)
13 Bleeding Volume Test: A Double-Blind Crossover Randomized Clinical Trial of an In-Vivo On-Line Test for Aspirin Effect and Resistance Unknown status NCT01047722 Phase 1 Aspirin ingestion followed by doing a Bleeding Volume Test
14 Mechanism Based Resistance to Aspirin Completed NCT00948987 Phase 1 Aspirin
15 Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary PCI and CABG Population Unknown status NCT01408927
16 Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient Unknown status NCT01045785
17 Genotypic and Phenotypic Correlates of Resistance to Anti-platelet Actions of Aspirin in an At-risk Patient Population and in the General Population Completed NCT01361620 aspirin
18 Assessment of Aspirin and Clopidogrel Resistance in Ischemic Heart Disease Using Multiplate Function Analyser and it's Correlation With Major Adverse Cardiac Events Completed NCT00742430
19 Prevalence of Aspirin Resistance in Hemodialysis Patients Completed NCT00792272
20 Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease Completed NCT00753935 Early Phase 1 enteric-coated aspirin;Chewable aspirin
21 Aspirin Responsiveness in Women With Coronary Artery Disease Completed NCT01406990
22 Validation of an Ex Vivo Cyclooxygenase-1 Catalytic Assay in Humans Completed NCT00761891
23 Comparative Evaluation of Aspirin Resistance With Point-of-Care Testing - Danish Aspirin Resistance Trial (DANART) - Pilot Study Completed NCT00389129 acetylsalicylic acid
24 Cardiovascular Events at One Year of Patients Hospitalized for Critical Limb Ischaemia and Aspirin Resistant Using the VerifyNow®. Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia Completed NCT01104441
25 Efficacité du Traitement antiagrégant Par Acide acétylsalicylique en Chirurgie Vasculaire mesurée Par agrégométrie Par impédance Completed NCT01432652
26 The Effect of Serum LDL Lowering on Aspirin Resistance Completed NCT00466154 Aspirin
27 Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial) Completed NCT03930875
28 The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)-A Prospective Multicenter Cohort Study- Completed NCT00250380
29 Laboratory Aspirin Resistance in Coronary Artery Disease Patients With or Without Diabetes Mellitus Completed NCT00563875 acetylsalicylic acid
30 Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients Completed NCT01364779
31 Enteric Coating as a Factor in Aspirin Resistance Completed NCT00531362 Plain aspirin
32 Association of PeriOPerative Aspirin-ResisTance and CardioVascular Outcome Not yet recruiting NCT04053894
33 Aspirin Resistance Following Coronary Bypass Surgery Terminated NCT00260377
34 Obstructive Sleep Apnea and Aspirin Resistance in Type-2 Diabetic Patients Terminated NCT01788930
35 Measurement of Platelet Dense Granule Release in Healthy Volunteers Withdrawn NCT00942617 Aspirin
36 Aspirin Resistance in Women With Migraine Withdrawn NCT01257893 Aspirin (acetylsalicylic acid);Placebo

Search NIH Clinical Center for Aspirin Resistance

Genetic Tests for Aspirin Resistance

Anatomical Context for Aspirin Resistance

MalaCards organs/tissues related to Aspirin Resistance:

40
Heart, Whole Blood, Endothelial, Kidney, Skeletal Muscle

Publications for Aspirin Resistance

Articles related to Aspirin Resistance:

(show top 50) (show all 739)
# Title Authors PMID Year
1
Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. 57 61
21844189 2011
2
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. 57 61
11940542 2002
3
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. 61 57
11472699 2001
4
Development of aspirin resistance in persons with previous ischemic stroke. 57 61
7974569 1994
5
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? 57
11940535 2002
6
One hundred years of aspirin. 57
9259670 1997
7
Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. 57
8312766 1994
8
Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. 57
8054013 1994
9
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. 57
8298418 1994
10
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. 57
1907252 1991
11
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. 57
5284360 1971
12
Aspirin selectively inhibits prostaglandin production in human platelets. 57
5284361 1971
13
Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. 57
13013156 1953
14
Influence of low-dose aspirin, resistance exercise, and sex on human skeletal muscle PGE2 /COX pathway activity. 61
33661544 2021
15
Clinical Post-operative Bleeding During Minor Oral Surgical Procedure and In Vitro Platelet Aggregation in Patients on Aspirin Therapy: Are they Coherent? 61
33584054 2021
16
Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on clopidogrel. 61
32973115 2021
17
Authors' reply: Aspirin resistance and blunt cerebrovascular injuries among female patients. 61
33060536 2021
18
In response to: Female sex as a risk factor for blunt cerebrovascular injuries and aspirin resistance. 61
33060535 2021
19
Unfavorable Changes of Platelet Reactivity on Clopidogrel Therapy Assessed by Impedance Aggregometry Affect a Larger Volume of Acute Ischemic Lesions in Stroke. 61
33673437 2021
20
Chronic Application of Low-Dose Aspirin Affects Multiple Parameters of Three Blood Cellular Types and Antithrombin Activity: A 1:1:1 Propensity Score Matching Analysis. 61
33105321 2021
21
Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome. 61
33441016 2021
22
A Narrative Review of Aspirin Resistance in VTE Prophylaxis for Orthopaedic Surgery. 61
33037568 2020
23
Determinants of aspirin resistance in patients with type 2 diabetes. 61
31783142 2020
24
Platelet function in stroke/transient ischemic attack patients treated with tocotrienol. 61
32686874 2020
25
Modulation of microRNAs by aspirin in cardiovascular disease. 61
31444100 2020
26
Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation. 61
32696878 2020
27
Aspirin Resistance Significantly Influences Clinical and Economic Burden in Cardiac Surgery Patients. 61
31586618 2020
28
Older adults with frailty syndrome present an altered platelet function and an increased level of circulating oxidative stress and mitochondrial dysfunction biomarker GDF-15. 61
31926293 2020
29
Aspirin Resistance Affects Medium-Term Recurrent Vascular Events after Cerebrovascular Incidents: A Three-Year Follow-up Study. 61
32204465 2020
30
Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction. 61
32027781 2020
31
Resistance of aspirin during and after pregnancy: A longitudinal cohort study. 61
31865169 2020
32
Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis. 61
32509239 2020
33
Performance comparison of platelet function analyzers in cardiology patients: VerifyNow and Anysis-200 aspirin assays. 61
32538826 2020
34
[Expanding the possibilities of antithrombotic therapy of cerebrovascular pathology]. 61
32490629 2020
35
Long Non-Coding RNA H19 Positively Associates With Aspirin Resistance in the Patients of Cerebral Ischemic Stroke. 61
33101034 2020
36
The emergent phenomenon of aspirin resistance: insights from genetic association studies. 61
31957546 2020
37
Aspirin Resistance Incidence and Associations Between Aspirin Effect and Outcomes in Cardiac Surgery. 61
31238032 2019
38
Effects of aspirin resistance and mean platelet volume on vascular access failure in hemodialysis patients. 61
30025441 2019
39
Aspirin resistance mediated by oxidative stress-induced 8-Isoprostaglandin F2. 61
30989683 2019
40
The potential of acetylsalicylic acid and vitamin E in modulating inflammatory cascades in chickens under lipopolysaccharide-induced inflammation. 61
31533824 2019
41
Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. 61
31511539 2019
42
Correlation of Cardiovascular Risk Factors and Biomarkers With Platelet Reactivity in Coronary Artery Disease. 61
30418226 2019
43
Aspirin Resistance: Cardiovascular Risk Game Changer. 61
29757761 2019
44
The dilemma of aspirin resistance in obese patients. 61
31660303 2019
45
[Network pharmacology-based study on mechanisms of Danhong Injection in treatment of aspirin resistance]. 61
31359682 2019
46
Metabolic Syndrome and the Effectiveness of Low-dose Aspirin on Reproductive Outcomes. 61
30985534 2019
47
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke. 61
30795966 2019
48
Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study. 61
31007424 2019
49
Obesity and laboratory aspirin resistance in high-risk pregnant women treated with low-dose aspirin. 61
30786253 2019
50
Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. 61
31356179 2019

Variations for Aspirin Resistance

Expression for Aspirin Resistance

Search GEO for disease gene expression data for Aspirin Resistance.

Pathways for Aspirin Resistance

Pathways related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 ITGB3 F5 F2 APOB
2
Show member pathways
12.02 PTGS2 PTGS1 ITGB3
3
Show member pathways
11.75 ITGB3 F2 APOB
4 11.51 PTGS2 ITGB3
5 11.43 PTGS1 ITGB3 F2
6 11.31 PTGS2 PTGS1
7 11.29 PTGS2 PTGS1
8
Show member pathways
11.26 PTGS2 PTGS1 F2 APOB
9 10.99 PTGS2 PTGS1
10 10.94 PTGS2 PTGS1
11
Show member pathways
10.91 PTGS2 PTGS1
12 10.84 PTGS1 ITGB3 F2
13 10.81 PTGS2 PTGS1
14 10.77 PTGS2 PTGS1
15 10.65 PTGS2 PTGS1
16 10.43 PTGS2 PTGS1

GO Terms for Aspirin Resistance

Cellular components related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 8.92 PTGS2 F5 F2 APOB

Biological processes related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.5 F5 F2 APOB
2 response to organic substance GO:0010033 9.49 PTGS2 APOB
3 cellular oxidant detoxification GO:0098869 9.48 PTGS2 PTGS1
4 fatty acid biosynthetic process GO:0006633 9.46 PTGS2 PTGS1
5 regulation of blood pressure GO:0008217 9.43 PTGS2 PTGS1
6 leukocyte migration GO:0050900 9.43 ITGB3 F2 APOB
7 hemostasis GO:0007599 9.4 F5 F2
8 prostaglandin metabolic process GO:0006693 9.37 PTGS2 PTGS1
9 blood coagulation GO:0007596 9.33 ITGB3 F5 F2
10 prostaglandin biosynthetic process GO:0001516 8.96 PTGS2 PTGS1
11 cyclooxygenase pathway GO:0019371 8.62 PTGS2 PTGS1

Molecular functions related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dioxygenase activity GO:0051213 9.16 PTGS2 PTGS1
2 peroxidase activity GO:0004601 8.96 PTGS2 PTGS1
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1

Sources for Aspirin Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....